Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844
This study is recruiting at 10 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumors
- Advanced Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Ensem Therapeutics
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Hoag Memorial Hospital Presbyterian · Newport Beach, CA
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, CA
Connecticut · 1
- Yale University, Yale Cancer Center · New Haven, CT
Massachusetts · 2
- Beth Israel Deaconess Medical Center · Boston, MA
- Dana-Farber Cancer Institute · Boston, MA
North Carolina · 1
- Carolina BioOncology Institute · Huntersville, NC
Texas · 2
- The University of Texas MD Anderson Cancer Center · Houston, TX
- START · San Antonio, TX
Virginia · 1
- NEXT · Fairfax, VA
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.